Mergers & Acquisitions

Cancer treatment company, Micromet announce merger agreement

Published in Cancer Weekly, January 31st, 2006

CancerVax Corp. (CNVX), a biotechnology company focused on the research, development, and commercialization of biological products for the treatment of cancer, and Micromet, AG, a privately held European biopharmaceutical companies focused on the development of antibody-based drugs, announced the signing of a definitive merger agreement.

The merger is expected to create a transatlantic, Nasdaq-listed company with a highly differentiated drug-development pipeline focused on oncology, autoimmune, and inflammatory diseases, and a strong, proprietary technology base for the development of antibody-based product candidates.

"We believe that the proposed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-01-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry